ARTICLE | Company News
Cellectis, Pregenen deal
July 4, 2011 7:00 AM UTC
The companies partnered to develop genome engineering technology such as meganucleases and meganuclease vector technology. The companies will own the IP, with Cellectis having an option to license ex...